| Molecular Formula | C39H67N5O7 |
| Molar Mass | 717.98 |
| Density | 1.088±0.06 g/cm3(Predicted) |
| Melting Point | >90°C (dec.) |
| Boling Point | 873.5±65.0 °C(Predicted) |
| Solubility | DMSO: ≥ 48 mg/mL |
| Appearance | Solid |
| Color | White to Off-White |
| pKa | 13.66±0.20(Predicted) |
| Storage Condition | -20°C Freezer |
| In vitro study | When coupled to cAC10, MMAE at CD30 in vitro, when coupled to anti-cd79b antibody, anti-CD79b-vcMMAE has very potent and broad activity against a large group of NHL cell lines. When coupled with an anti-HER2 antibody, hertuzumab-vc-MMAE can be fully taken up and effectively kill HER2 overexpressing tumor cells. |
| In vivo study | In The Karpas 299 ALCL model, cAC10-vcMMAE (1 mg/kg, I. v.) complete, long-lasting tumor regression was induced, whereas free MMAE (0.36 mg/kg) produced no detectable antitumor activity. In the NHL mouse xenograft model, anti-CD79b-vcMMAE (7 mg/kg, p.o.) significantly resulted in sustained complete tumor regression. |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.393 ml | 6.964 ml | 13.928 ml |
| 5 mM | 0.279 ml | 1.393 ml | 2.786 ml |
| 10 mM | 0.139 ml | 0.696 ml | 1.393 ml |
| 5 mM | 0.028 ml | 0.139 ml | 0.279 ml |